chidamide + etoposide + cisplatin + carboplatin

This combination regimen, being investigated by Peking Union Medical College Hospital, consists of the histone deacetylase (HDAC) inhibitor chidamide (Epidaza) administered in conjunction with the standard chemotherapy backbone of etoposide and a platinum agent (either cisplatin or carboplatin). Chidamide is a benzamide-class HDAC inhibitor that selectively targets HDAC1, 2, 3, and 10, thereby modulating the epigenetic landscape to reverse drug resistance and inhibit tumor progression. Etoposide functions by inhibiting topoisomerase II, leading to DNA strand breaks, while cisplatin and carboplatin act as DNA alkylating agents that form inter- and intra-strand cross-links. This synergistic approach is specifically being evaluated as a first-line treatment for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC), a rare and aggressive malignancy with limited treatment options.

Brand names

Epidaza

Other names

Chidamide plus EP/ECChidamide + Etoposide + Cisplatin/Carboplatinchidamide + etoposide + cisplatin + carboplatin-Peking Union Medical College Hospital-extrapulmonary neuroendocrine carcinoma